Type of support |
Approvals 2001-2023 (US$)(17 Sep 2019) |
Commitments 2001-2023 (US$)(17 Sep 2019) |
Disbursements 2000-2019 (US$)(17 Sep 2019) |
% Disbursed(17 Sep 2019) |
2002 |
2003 |
2004 |
2005 |
2006 |
2007 |
2008 |
2009 |
2010 |
2011 |
2012 |
2013 |
2014 |
2015 |
2016 |
2017 |
2018 |
2019 |
2020 |
2021 |
2022 |
|
Total |
$34,810,722 |
$41,807,263 |
$34,667,207 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash Support (CASHSUPP) |
$195,000 |
$195,000 |
$195,000 |
100% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cold Chain Equipment Optimisation Platform (CCEOP) |
$693,289 |
$693,289 |
$528,102 |
76% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Health system strengthening (HSS 1) |
|
|
|
N/A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Health system strengthening (HSS 2) |
$3,330,818 |
$5,546,359 |
$1,744,995 |
52% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
HepB mono (NVS) |
$455,977 |
$455,977 |
$455,977 |
100% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Hib mono (NVS) |
$410,021 |
$410,021 |
$410,021 |
100% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
HPV (NVS) |
$270,000 |
$2,226,500 |
$269,550 |
100% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
HPV Demo (NVS) |
$282,258 |
$282,258 |
$282,666 |
100% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
HPV MAC (NVS) |
$820,000 |
$820,000 |
$820,450 |
100% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
HPV MAC - Op costs (OPC) |
$70,286 |
$70,286 |
$70,286 |
100% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Immunisation services support (ISS) |
$671,640 |
$671,640 |
$671,640 |
100% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Injection Safety Devices (NVS) |
$111,500 |
$197,500 |
$138,608 |
124% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Injection safety support (INS) |
$101,184 |
$101,184 |
$101,184 |
100% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
IPV (NVS) |
$364,779 |
$364,779 |
$391,390 |
107% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Measles (NVS) |
$139,080 |
$139,080 |
$139,774 |
100% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Measles-Rubella (NVS) |
$629,937 |
$629,937 |
$629,937 |
100% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Meningitis A (NVS) |
$75,500 |
$141,500 |
$81,120 |
107% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Meningitis A - campaign (NVS) |
$788,739 |
$788,739 |
$788,739 |
100% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Meningitis A - mini catch-up campaign (NVS) |
$223,500 |
$223,500 |
$234,867 |
105% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Meningitis A - mini catch-up op.costs (OPC) |
$198,424 |
$198,424 |
$198,424 |
100% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Meningitis A - operational costs (OPC) |
$727,500 |
$727,500 |
$727,500 |
100% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
MR - Operational costs (OPC) |
$521,500 |
$521,500 |
$521,500 |
100% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Penta (NVS) |
$4,672,363 |
$4,967,363 |
$4,714,654 |
101% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pneumo (NVS) |
$10,341,764 |
$11,946,764 |
$11,967,281 |
116% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Product Switch Grant (PSG) |
$29,999 |
$29,999 |
$29,999 |
100% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Rotavirus (NVS) |
$3,703,732 |
$4,476,232 |
$3,671,611 |
99% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Tetra DTP-Hib (NVS) |
$3,675,683 |
$3,675,683 |
$3,675,683 |
100% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Vaccine Introduction Grant (VIG) |
$1,306,249 |
$1,306,249 |
$1,206,249 |
92% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Red line on table indicates duration of support based on commitments.
Commitments: Multi-year programme budgets endorsed in principle by the Gavi Board. These become financial commitments upon approval each year for the following calendar year.
Approvals: Total Approved for funding
Download data for commitments, approvals & disbursements in XLS format